Obsessive-Compulsive Disorder Market

Market Overview:

The 7 major obsessive-compulsive disorder markets reached a value of US$ 643.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,078.4 Million by 2034, exhibiting a growth rate (CAGR) of 4.8% during 2024-2034.

The obsessive-compulsive disorder market has been comprehensively analyzed in IMARC's new report titled "Obsessive-Compulsive Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Obsessive-compulsive disorder (OCD) refers to a mental health condition characterized by intrusive, recurrent thoughts (obsessions) and repetitive, ritualistic behaviors or mental acts that patients feel compelled to perform. This disease causes significant distress and can interfere with daily functioning, relationships, and the overall quality of life. The common symptoms of the ailment include fear of losing control, concerns about order, symmetry or exactness, counting or tapping rituals, anxiety, agitation, a sense of guilt or shame, aggression, intense stress, etc. Individuals suffering from the disorder may additionally experience impulsivity, repetitive movements, social isolation, compulsive hoarding, panic attacks, depression, food aversion, nightmares, etc. OCD is typically diagnosed through a combination of clinical evaluation, assessment of indications, and neurological tests. The healthcare professional will validate a diagnosis by referring to the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Various other self-report questionnaires or rating scales may be used to determine the frequency and severity of disease symptoms. These scales include the Yale-brown obsessive-compulsive scale, the obsessive-compulsive inventory, the dimensional obsessive-compulsive scale, etc.

The rising prevalence of imbalances in specific neurotransmitters, such as serotonin, dopamine, glutamate, etc., that can lead to abnormalities in brain structure and functioning is primarily driving the obsessive-compulsive disorder market. In addition to this, the increasing incidences of several associated risk factors, including certain neurological conditions, traumatic events, chronic stress, genetic mutations, etc., are further augmenting the market growth. Moreover, the emerging popularity of selective serotonin reuptake inhibitors (SSRIs), such as sertraline and fluoxetine, which work by inhibiting neurochemical reuptake and providing symptom relief among patients, is also creating a positive outlook for the market. Apart from this, the widespread adoption of habit reversal training procedures that aid individuals suffering from OCD to regain a sense of control over their thoughts and actions is further bolstering the market growth. Additionally, the escalating utilization of dialectical behavior therapy, since it combines cognitive-behavioral techniques with mindfulness and emotional regulation strategies to enhance distress tolerance and reduce compulsiveness in patients, is expected to drive the obsessive-compulsive disorder market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the obsessive-compulsive disorder market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for obsessive-compulsive disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the obsessive-compulsive disorder market in any manner.

Key Highlights:

• Obsessive-compulsive disorder is a common psychiatric illness that affects one to three percent of the global population.
• Obsessive-compulsive disorder has a lifetime frequency of 2-3% in the U.S.
• The disorder usually begins early in life and has a chronic source. The most prevalent demographic range impacted is between ages 18 and 29 years.
• Nearly a quarter of males display symptoms before age 10, whereas the disorder usually emerges during adolescence for females.
• Women are approximately 1.6 times more likely than men to be impacted by the condition.

Drugs:

PROZAC is used to treat obsessive-compulsive disorder in adults and children aged 7-17 years. The drug is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Prozac is administered orally.

BHV-4157 is a third-generation prodrug and a novel chemical entity that regulates glutamate, the most common excitatory neurotransmitter in the human body. BHV-4157's principal mode of action is to normalize glutamate levels at synapses. BHV-4157 enhances glutamate uptake from the peri-synaptic region by increasing the expression and function of excitatory amino acid transporters on glial cells, which play an important role in removing glutamate from the synapse.

SYNP-101 is a synthetic psilocybin drug candidate being developed by Ceruvia Lifesciences as a treatment for obsessive-compulsive disorder. The FDA approved Ceruvia's investigational new drug (IND) application for a Phase II clinical trial of SYNP-101. The primary aim of the trial is to assess if a single dosage of SYNP-101 reduces obsessive-compulsive disorder symptoms for up to 12 weeks.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the obsessive-compulsive disorder market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the obsessive-compulsive disorder market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current obsessive-compulsive disorder marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the obsessive-compulsive disorder market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the obsessive-compulsive disorder market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the obsessive-compulsive disorder market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of obsessive-compulsive disorder across the seven major markets?
• What is the number of prevalent cases (2018-2034) of obsessive-compulsive disorder by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of obsessive-compulsive disorder by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with obsessive-compulsive disorder across the seven major markets?
• What is the size of the obsessive-compulsive disorder patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of obsessive-compulsive disorder?
• What will be the growth rate of patients across the seven major markets?
   

Obsessive-Compulsive Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for obsessive-compulsive disorder drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the obsessive-compulsive disorder market?
• What are the key regulatory events related to the obsessive-compulsive disorder market?
• What is the structure of clinical trial landscape by status related to the obsessive-compulsive disorder market?
• What is the structure of clinical trial landscape by phase related to the obsessive-compulsive disorder market?
• What is the structure of clinical trial landscape by route of administration related to the obsessive-compulsive disorder market?